Brooks Laboratories Limited

BSE: 533543 NSE: BROOKS
Brooks Laboratories Limited - pharma in Nalagarh, Himachal Pradesh, India. FY 2026 financials & compliance.
CIN L24232HP2002PLC000267 Incorporated 23 January 2002 ROC Himachal Pradesh HQ Nalagarh, Himachal Pradesh, India
Active Listed - NSE: BROOKS · BSE: 533543 Public Limited Company pharma
Data last updated
Market Cap
₹161 Cr
BROOKS · NSE
Share Price
₹53.52
-4.09% today
Revenue
₹85.74 Cr
FY 2025-26 · -13.2% YoY
EBITDA
₹7.07 Cr
Margin 8.2%
Net Profit
₹24.30 Cr
FY 2025-26 · +9998.0% YoY
P/E (TTM)
12.4x
P/B 1.3x
Authorised capital
₹30 Cr
Registered with MCA
Paid-up capital
₹29.46 Cr
Issued & subscribed

About Brooks Laboratories Limited

Data last updated:

Brooks Laboratories Limited is a public limited company based in Nalagarh, Himachal Pradesh, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 23 January 2002 and has been in existence for over 24 years.

The company is registered with the Registrar of Companies (ROC), Himachal Pradesh, under CIN L24232HP2002PLC000267. Its GSTIN is 02AACCB5316P1ZR (Himachal Pradesh). The company holds 7 GST registrations, of which 5 are active. Its shares are listed on BSE: 533543 and NSE: BROOKS.

The company has an authorised share capital of ₹30 Cr and a paid-up capital of ₹29.46 Cr. It is led by directors including Jitendrapratap Rambahadur Singh (Whole-Time Director) and Bhushan Singh Rana (Whole-Time Director).

Its last annual general meeting (AGM) was held on 26 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Village Kishanpura Nalagarh Road Baddi, Himachal Pradesh, India – 174101.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹85.74 Cr, a growth of 3.85% compared to the previous year. The net worth stands at ₹122.66 Cr (up 25.02% YoY). Total assets are valued at ₹132.78 Cr (up 24.02% YoY).

The company has about 289 employees on its provident fund (EPFO) records.

The company is associated with 1 brand: Brooks Laboratories. As per MCA filings, the company has open charges of ₹77.33 Cr and satisfied charges of ₹115.74 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website brookslabs.net.

Company Details of Brooks Laboratories Limited
CIN L24232HP2002PLC000267
Registration Number 000267
Incorporation Date 23 January 2002
ROC Himachal Pradesh
Listing Status Listed (BSE: 533543, NSE: BROOKS)
Company Status Active
Date of Last AGM 26 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Jitendrapratap Rambahadur Singh Whole-Time Director Bhushan Singh Rana Whole-Time Director Durga Shankar Maity Whole-Time Director
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    brookslabs.net
  • Social Media
  • Registered Address
    Village Kishanpura Nalagarh Road Baddi, Himachal Pradesh, India – 174101
  • Industry
    Pharma, Drug Formulation & Development
Comprehensive company report
Brooks Laboratories Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
  • One PDF report, delivered after checkout
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Unlock the full Brooks Laboratories Limited report

Financials, compliance, directors, charges, ownership and filings for Brooks Laboratories Limited in one report.

10-year financials Directors & ownership Charges & compliance

CIN History of Brooks Laboratories

Brooks Laboratories has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L24232HP2002PLC000267, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L24232HP2002PLC000267Current
U24232PB2002PLC024910Previous
L24232PB2002PLC024910Previous

Associated Brands with Brooks Laboratories

Brooks Laboratories operates one associated brand: Brooks Laboratories. Each brand links to its own profile.

BrandDescriptionWebsite
Brooks Laboratories
Manufacturer of pharmaceutical injectables, tablets, and oral suspensionsbrookslabs.net

Business Activity of Brooks Laboratories

The main business activity of Brooks Laboratories is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group CodeDescription of Main ActivityBusiness Activity CodeDescription of Business ActivityTurnover Percentage
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical productsLocked
Premium access

Business activity turnover details for Brooks Laboratories Limited

Turnover share and past changes in activity are in the company report.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Verified entity values are shown only after access is granted.

Auditor Details of Brooks Laboratories

Brooks Laboratories Limited is audited by SGCO & CO for the financial year 2024.

NameStatusAppointment DateCessation Date
SGCO & COLockedLockedLocked
Premium access

Complete auditor history for Brooks Laboratories Limited

Appointment and cessation dates and past auditor changes are in the company report.

  • Appointment status
  • Appointment dates
  • Cessation dates
  • Auditor changes

Verified entity values are shown only after access is granted.

Board of Directors of Brooks Laboratories Limited

Brooks Laboratories has 6 current directors and 21 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Jitendrapratap Rambahadur SinghWhole-Time Director23 Nov 20223 Years 10 MonthsCurrent
Lalit MahajanDirector07 Aug 20242 Years 1 MonthsCurrent
Usha SinghDirector07 Aug 20242 Years 1 MonthsCurrent
Manav MahajanDirector28 Sep 20242 Years 0 MonthsCurrent
Bhushan Singh RanaWhole-Time Director23 Aug 20233 Years 1 MonthsCurrent
Durga Shankar MaityWhole-Time Director07 Jul 20233 Years 2 MonthsCurrent
View all directors

Financials of Brooks Laboratories Limited FY 2025-26 filings available

Brooks Laboratories Limited reported revenue of ₹85.74 Cr (up 3.85% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹85.74 Cr
+3.9% YoY
EBITDA
₹7.07 Cr
+187.9% YoY
Profit After Tax
₹24.30 Cr
+343.2% YoY
Net Worth
₹123 Cr
+25.0% YoY
Total Assets
₹133 Cr
+24.0% YoY
Total Debt
₹8.52 Cr
+12.4% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Income statement
Revenue85.7482.5679.4963.2091.1877.25
Revenue growth-13.2%-6.9%+4.8%-11.9%+37.5%+9997.0%
EBITDA7.07(8.04)(17.86)(29.72)(14.27)0.53
EBITDA margin+8.3%-9.7%-22.5%-47.0%-15.7%+0.7%
Profit before tax24.59(9.79)(19.55)(38.36)(23.92)(8.97)
Net profit24.30(9.99)(19.59)(21.25)(11.44)(19.31)
Net profit margin+28.3%-12.1%-24.6%-33.6%-12.6%-25.0%
EPS (₹)8.35(3.38)(7.46)(8.46)(4.57)(7.84)
Balance sheet
Total assets13310772.6882.49162112
Net worth12398.1165.5973.9587.4979.15
Total debt8.527.585.646.5125.2631.38
Cash & bank7.551.250.691.083.811.70
Net working capital22.0117.2413.290.4927.430.69
Cash flow
Cash from operations9.292.63(9.80)(14.49)(37.44)4.46
Cash from investing(2.92)(45.14)0.180.49(24.91)(5.13)
Cash from financing0.1742.439.7211.4164.071.16
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue22.9620.2116.5723.4525.5123.3220.5220.79
Revenue growth (YoY)-10.0%-13.3%-19.3%+12.8%+42.3%+31.6%-5.7%-14.5%
Other income0.181.355.326.137.150.620.030.20
EBITDA(1.34)0.680.742.523.12(1.25)(1.49)(3.41)
EBITDA margin-5.8%+3.4%+4.5%+10.7%+12.2%-5.4%-7.3%-16.4%
Depreciation0.420.410.390.390.390.390.380.43
Interest0.210.090.160.280.300.260.280.32
Profit before tax(1.79)1.535.517.989.58(1.28)(2.12)(3.96)
Tax0.000.000.000.000.000.180.000.00
Net profit(1.79)1.535.517.989.58(1.46)(2.12)(3.96)
EPS (₹)(0.61)0.521.872.713.25(0.54)(0.82)(1.51)
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue85.7482.5679.4955.5476.9777.2769.69
Revenue growth+1.4%+1.8%+24.3%-18.3%-1.6%+3.7%+16.1%
EBITDA7.074.983.26(5.81)1.880.94(3.92)
EBITDA margin+8.3%+6.0%+4.1%-10.5%+2.4%+1.2%-5.6%
Profit before tax5.813.231.57(8.18)0.67(8.44)(13.51)
Net profit5.523.031.53(8.19)0.41(15.53)(23.19)
Net profit margin+6.4%+3.7%+1.9%-14.8%+0.5%-20.1%-33.3%
EPS (₹)1.971.040.58(3.31)0.27(6.31)(9.87)
Balance sheet
Total assets13112476.6365.3173.1174.37128
Net worth12111569.5356.7865.0064.2198.41
Total debt8.527.585.646.515.978.4027.64
Cash & bank7.551.250.691.081.080.881.53
Net working capital22.0117.2413.290.496.696.717.82
Cash flow
Cash from operations9.292.63(9.80)0.553.12(0.90)(9.39)
Cash from investing(2.92)(45.14)0.18(0.40)1.12(0.74)(2.33)
Cash from financing0.1742.439.72(0.21)(4.22)1.319.61
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue22.9620.2116.5723.4525.5123.3220.5220.79
Revenue growth (YoY)-10.0%-13.3%-19.3%+12.8%+42.3%+31.6%-5.7%-14.5%
Other income0.180.440.130.390.220.620.030.20
Total expenses21.1019.5315.8320.9322.3921.7418.9419.28
EBITDA1.860.680.742.523.121.581.581.51
EBITDA margin+8.1%+3.4%+4.5%+10.7%+12.2%+6.8%+7.7%+7.3%
Depreciation0.420.410.390.390.390.390.380.43
Interest0.210.090.160.280.300.260.280.32
Profit before tax1.410.620.322.242.651.550.950.96
Tax0.000.000.000.000.000.180.000.00

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 04 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue22.9620.2116.5723.4525.5123.3220.5220.79
Revenue growth (YoY)-10.0%-13.3%-19.3%+12.8%+42.3%+31.6%-5.7%-14.5%
Other income0.181.355.326.137.150.620.030.20
EBITDA(1.34)0.680.742.523.12(1.25)(1.49)(3.41)
EBITDA margin-5.8%+3.4%+4.5%+10.7%+12.2%-5.4%-7.3%-16.4%
Depreciation0.420.410.390.390.390.390.380.43
Interest0.210.090.160.280.300.260.280.32
Profit before tax(1.79)1.535.517.989.58(1.28)(2.12)(3.96)
Tax0.000.000.000.000.000.180.000.00
Net profit(1.79)1.535.517.989.58(1.46)(2.12)(3.96)
EPS (₹)(0.61)0.521.872.713.25(0.54)(0.82)(1.51)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Revenue85.7482.5679.4963.2091.1877.25
Revenue growth-13.2%-6.9%+4.8%-11.9%+37.5%+9997.0%
Other income19.950.880.920.570.800.74
Total expenses78.6790.6097.3592.9210576.72
Employee cost14.6212.4510.0916.0016.8512.04
EBITDA7.07(8.04)(17.86)(29.72)(14.27)0.53
EBITDA margin+8.3%-9.7%-22.5%-47.0%-15.7%+0.7%
Depreciation1.591.601.777.037.357.14
Interest0.841.030.842.183.103.10
Profit before tax24.59(9.79)(19.55)(38.36)(23.92)(8.97)
Tax0.000.180.03(7.32)(4.59)10.38
Net profit24.30(9.99)(19.59)(21.25)(11.44)(19.31)
Net profit margin+28.3%-12.1%-24.6%-33.6%-12.6%-25.0%
EPS (₹)8.35(3.38)(7.46)(8.46)(4.57)(7.84)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Equity & liabilities
Share capital29.4629.4626.2524.7024.7024.70
Reserves & surplus93.2068.6539.3449.2562.7954.45
Shareholders' funds (net worth)12398.1165.5973.9587.4979.15
Minority interest0.000.000.000.0046.830.00
Secured loans7.286.065.045.6624.2131.38
Unsecured loans1.241.520.600.851.050.00
Total debt8.527.585.646.5125.2631.38
Total liabilities13310772.6882.49162112
Assets
Gross block26.0025.1523.2722.83143133
Net block14.5213.9813.6715.00110108
Capital work in progress1.190.000.000.0015.110.83
Investments92.3473.5542.9164.030.060.02
Inventories11.029.209.6111.3027.5223.60
Sundry debtors16.1119.9916.3212.7517.6613.70
Cash & bank balances7.551.250.691.083.811.70
Loans & advances2.733.434.432.4712.198.36
Total current assets37.4133.8731.0527.6061.1847.36
Total current liabilities15.4016.6317.7627.1133.7546.67
Net working capital22.0117.2413.290.4927.430.69
Total assets13310772.6882.49162112
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Opening cash0.040.130.022.610.880.40
Net cash from operating activities9.292.63(9.80)(14.49)(37.44)4.46
Net cash from investing activities(2.92)(45.14)0.180.49(24.91)(5.13)
Net cash from financing activities0.1742.439.7211.4164.071.16
Net change in cash6.54(0.08)0.10(2.58)1.720.49
Closing cash7.551.250.691.083.811.70
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Growth
Sales growth+3.9%+3.9%+25.8%-30.7%+18.0%+9997.0%
EBITDA growth+9998.0%+55.0%+39.9%-108.3%-+9997.0%
PBT growth+9998.0%+49.9%+49.0%-60.4%-166.7%+9997.0%
Net income growth+9998.0%+49.0%+7.8%-85.8%+40.8%+9997.0%
Revenue CAGR (3Y)+10.7%-3.3%+1.0%---
EBITDA CAGR (3Y)--17.4%----
Profitability & leverage
Net income margin+28.7%-12.1%-24.6%-49.1%-21.2%-25.1%
Return on capital employed-0.0%0.0%0.0%0.0%0.0%
Return on net worth-0.0%0.0%0.0%0.0%0.0%
Debt / equity-0.080.090.200.400.40
Long-term debt / equity-0.010.010.070.170.18
Interest cover15.33-10.68-4.28-5.93-14.34-46.90
Efficiency & per share
Fixed asset turnover-3.413.450.760.660.58
Inventory turnover-8.787.603.263.563.27
Debtors turnover-4.555.474.165.815.64
EPS (₹)8.35(3.38)(7.46)(8.46)(4.57)(7.84)
Dividend per share (₹)0.000.000.000.000.000.00
Book value per share (₹)41.6433.3024.9929.9435.4232.04
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue22.9620.2116.5723.4525.5123.3220.5220.79
Revenue growth (YoY)-10.0%-13.3%-19.3%+12.8%+42.3%+31.6%-5.7%-14.5%
Other income0.180.440.130.390.220.620.030.20
Total expenses21.1019.5315.8320.9322.3921.7418.9419.28
EBITDA1.860.680.742.523.121.581.581.51
EBITDA margin+8.1%+3.4%+4.5%+10.7%+12.2%+6.8%+7.7%+7.3%
Depreciation0.420.410.390.390.390.390.380.43
Interest0.210.090.160.280.300.260.280.32
Profit before tax1.410.620.322.242.651.550.950.96
Tax0.000.000.000.000.000.180.000.00
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue85.7482.5679.4955.5476.9777.2769.69
Revenue growth+1.4%+1.8%+24.3%-18.3%-1.6%+3.7%+16.1%
Other income1.170.880.920.120.950.960.41
Total expenses78.6777.5876.2361.3575.0976.3373.61
Employee cost14.6212.4510.0910.6510.8812.0411.16
EBITDA7.074.983.26(5.81)1.880.94(3.92)
EBITDA margin+8.3%+6.0%+4.1%-10.5%+2.4%+1.2%-5.6%
Depreciation1.591.601.771.721.497.096.65
Interest0.841.030.840.770.673.253.35
Profit before tax5.813.231.57(8.18)0.67(8.44)(13.51)
Tax0.000.180.030.000.007.1510.86
Net profit5.523.031.53(8.19)0.41(15.53)(23.19)
Net profit margin+6.4%+3.7%+1.9%-14.8%+0.5%-20.1%-33.3%
EPS (₹)1.971.040.58(3.31)0.27(6.31)(9.87)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital29.4629.4626.2524.7024.7024.7024.70
Reserves & surplus91.3985.6143.2832.0840.3039.5173.71
Shareholders' funds (net worth)12111569.5356.7865.0064.2198.41
Secured loans7.286.065.045.664.928.4026.88
Unsecured loans1.241.520.600.851.050.000.76
Total debt8.527.585.646.515.978.4027.64
Total liabilities13112476.6365.3173.1174.37128
Assets
Gross block26.0025.1523.2722.8321.0719.64133
Net block14.5213.9813.6715.0015.1414.96113
Capital work in progress1.190.000.000.001.120.020.11
Investments90.5390.5246.8646.8546.8446.810.02
Inventories11.029.209.6111.3016.5912.3813.77
Sundry debtors16.1119.9916.3212.7515.039.5915.56
Cash & bank balances7.551.250.691.081.080.881.53
Loans & advances2.733.434.432.474.342.497.05
Total current assets37.4133.8731.0527.6037.0425.3437.91
Total current liabilities15.4016.6317.7627.1130.3518.6330.09
Net working capital22.0117.2413.290.496.696.717.82
Total assets13112476.6365.3173.1174.37128
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash0.040.130.020.080.060.402.50
Net cash from operating activities9.292.63(9.80)0.553.12(0.90)(9.39)
Net cash from investing activities(2.92)(45.14)0.18(0.40)1.12(0.74)(2.33)
Net cash from financing activities0.1742.439.72(0.21)(4.22)1.319.61
Net change in cash6.54(0.08)0.10(0.06)0.02(0.33)(2.10)
Closing cash7.551.250.691.081.080.881.53
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+3.9%+3.9%+43.1%-27.8%-0.4%+10.9%+26.6%
EBITDA growth+42.0%+52.8%+9998.0%-+100.0%+9998.0%+53.1%
PBT growth+79.9%+105.7%+9998.0%-+9998.0%+37.5%+9.6%
Net income growth+82.2%+98.0%+9998.0%-+9998.0%+33.0%-54.9%
Revenue CAGR (3Y)+15.6%+2.4%+1.0%-7.3%+11.8%+11.5%+6.6%
EBITDA CAGR (3Y)-+38.4%+51.4%+14.0%---
Profitability & leverage
Net income margin+6.8%+3.7%+1.9%-14.7%+0.9%-20.2%-35.0%
Return on capital employed+4.3%+3.2%+2.7%0.0%+1.2%0.0%-7.7%
Return on net worth+4.0%+2.4%+1.9%0.0%+0.5%0.0%-24.0%
Debt / equity0.070.070.100.100.110.220.29
Long-term debt / equity0.010.010.010.010.020.080.13
Interest cover15.3330.4756.38-10.23171.79-52.85-31.69
Efficiency & per share
Fixed asset turnover3.353.413.452.533.781.020.53
Inventory turnover8.488.787.603.985.315.915.85
Debtors turnover4.754.555.474.006.256.145.17
EPS (₹)1.971.040.58(3.31)0.27(6.31)(9.87)
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)41.0239.0626.4922.9826.3125.9939.84
Want more history and ratios?
You're viewing the latest exchange-filed financials for Brooks Laboratories Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Brooks Laboratories Limited

Shareholding for the quarter ended Sep 2026: promoters hold 52.60%, foreign institutional investors hold 0.00%, domestic institutional investors hold 10.40% and retail and other public shareholders hold 37.00%.

Promoters: 52.60%DII (Domestic Institutional): 10.40%Retail & Others: 37.00%
Sep 2026
QUARTER
52.60% Promoters
10.40% DII (Domestic Institutional)
37.00% Retail & Others
Promoter holding - history
Now 52.60% · Sep 2026High 52.60% · Dec 2025Low 52.60% · Dec 2025
51%51.8%52.5%53.3%54%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 52.60%Mar 2026: 52.60%Jun 2026: 52.60%Sep 2026: 52.60%52.60%52.60%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters52.60%52.60%52.60%52.60%
Public47.40%47.40%47.40%47.40%

Group Structure of Brooks Laboratories Limited

Brooks Laboratories has 1 joint venture and 1 associated company. This group structure data is as of FY 2024. The table lists each entity with its relationship and holding.

1
Joint ventures
1
Associated companies

Charges & Borrowings of Brooks Laboratories

Open charges
₹77.33 Cr
Satisfied charges
₹115.74 Cr
Breakdown by lending institutions
Others₹75.81 Cr
Hdfc Bank Limited₹1.52 Cr
Latest charge details
DateLenderAmountStatus
04 May 2026Hdfc Bank Limited₹24.28 LakhOpen
24 Dec 2025Hdfc Bank Limited₹1.28 CrOpen
19 Dec 2024Others₹63.62 CrOpen
30 Jun 2024Others₹9.7 LakhOpen
19 Apr 2024Others₹9.04 LakhOpen

Total charge records: 25 View all charges

Employees and EPFO Compliance at Brooks Laboratories

Brooks Laboratories Limited has a workforce of 289 employees as of Mar 31, 2025.

Employee count
289
Active EPFO establishments
1
Employee growth
5.09%
Premium access

Employee and EPFO history for Brooks Laboratories Limited

Monthly headcount, contribution history and filing status are in the company report.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

GST Compliance of Brooks Laboratories

Brooks Laboratories has 7 GST registrations: 5 active and 2 cancelled or inactive. The first 4 active GSTINs are listed below.

Total GSTINs
7
Active
5
Cancelled / inactive
2
GSTINStateStatusRegistered on
02AACCB5316P1ZRHimachal PradeshActive01 Jul 2017
24AACCB5316P1ZLGujaratActive01 Jul 2017
19AACCB5316P1ZCWest BengalActive26 Aug 2017
27AACCB5316P2ZEMaharashtraActive19 Mar 2021
Premium access

GST registrations and filing compliance for Brooks Laboratories Limited

State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

Credit Ratings, Litigation & Regulatory Alerts for Brooks Laboratories

Premium access

Credit ratings, litigation, and regulatory alerts for Brooks Laboratories Limited

Credit ratings, court records and regulatory alerts are in the company report.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

MSME Payment Delays by Brooks Laboratories

Premium access

MSME payment history for Brooks Laboratories Limited

Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.

  • Outstanding amounts
  • Delay periods and reasons
  • MSME-1 filing history
  • Vendor payment signals

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Brooks Laboratories

Premium access

Corporate group structure for Brooks Laboratories Limited

Parent, subsidiary, associate and joint venture records with holdings are in the company report.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Brooks Laboratories

Premium access

MCA filings and documents for Brooks Laboratories Limited

Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Recent Activity on Brooks Laboratories

Charges
04 May 2026
A charge with Hdfc Bank Limited amounted to Rs. 0.24 Cr with Charge ID 101298868 was registered on 04 May 2026.
Charges
24 Dec 2025
A charge with Hdfc Bank Limited amounted to Rs. 1.28 Cr with Charge ID 101214075 was registered on 24 Dec 2025.
Activity
26 Sep 2025
Brooks Laboratories Limited last Annual general meeting of members was held on 26 Sep 2025 as per latest MCA records.
Activity
31 Mar 2025
Brooks Laboratories Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Himachal Pradesh.
Directors
23 Jan 2025
Krutika Mohan Rane was appointed as a Company Secretary on 23 Jan 2025 & has been associated with this company since 1 year 8 months.
Charges
31 Dec 2024
A charge registered on 25 Mar 2021 via Charge ID 100444147 with Indian Bank was fully satisfied on 31 Dec 2024.

Recent News on Brooks Laboratories

Frequently Asked Questions about Brooks Laboratories Limited

Brooks Laboratories is an active public limited company based in Nalagarh, Himachal Pradesh, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 23 January 2002 (24+ years old) and is registered under CIN L24232HP2002PLC000267. Listed on BSE: 533543 and NSE: BROOKS.

Brooks Laboratories reported revenue of ₹85.74 Cr for FY 2025-26 (up 3.85% YoY) based on consolidated financials.

Brooks Laboratories has 6 current directors:

The GSTIN of Brooks Laboratories is 02AACCB5316P1ZR, registered in Himachal Pradesh. The company has 7 GST registrations in all, of which 5 are active and 2 are cancelled or inactive. Other active GSTINs include 24AACCB5316P1ZL (Gujarat), 19AACCB5316P1ZC (West Bengal), 27AACCB5316P2ZE (Maharashtra).

The CIN (Corporate Identification Number) of Brooks Laboratories is L24232HP2002PLC000267. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Brooks Laboratories is listed on both BSE (code: 533543) and NSE (symbol: BROOKS).

Brooks Laboratories was incorporated on 23 January 2002, making it 24+ years old. It is registered with the Registrar of Companies, Himachal Pradesh.

Brooks Laboratories can be reached through the website brookslabs.net. Its registered office is in Nalagarh, Himachal Pradesh, India.

The registered office of Brooks Laboratories is at Village Kishanpura Nalagarh Road Baddi, Himachal Pradesh, India – 174101.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - compiled from official filings and updated regularly.

Subscription plans available